02 - References

References

918 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 13 References   1. Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009; 5:563–576.   2. Wong A, et al. Agomelatine overdose and related toxicity. Toxicol Commun 2018; 2:62–65.   3. US Food and Drug Administration. Drugs@FDA: FDA-­approved drugs. 2023; https://www.accessdata.fda.gov/scripts/cder/daf.   4. Buckley NA, et al. ‘Atypical’ antidepressants in overdose: clinical considerations with respect to safety. Drug Saf 2003; 26:539–551.   5. Mercerolle M, et al. A fatal case of bupropion (Zyban) overdose. J Anal Toxicol 2008; 32:192–196.   6. Murray B, et al. Single-­agent bupropion exposures: clinical characteristics and an atypical cause of serotonin toxicity. J Med Toxicol 2020; 16:12–16.   7. Overberg A, et al. Toxicity of bupropion overdose compared with selective serotonin reuptake inhibitors. Pediatrics 2019; 144:e20183295.   8. Robinson S. Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine. Am J Emerg Med 2022; 55:232.e3–232.e4.   9. Alibegović A, et al. Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. Forensic Sci Med Pathol 2019; 15:258–261. 10. Menchetti M, et al. Non-­fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 2009; 10:385–389. 11. White N, et al. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4:238–250. 12. Darracq MA, et al. A retrospective review of isolated duloxetine-­exposure cases. Clin Toxicol (Phila) 2013; 51:106–110. 13. Scanlon KA, et al. Comprehensive duloxetine analysis in a fatal overdose. J Anal Toxicol 2016; 40:167–170. 14. Jannsen-­Cilag Ltd. Summary of product characteristics. Spravato 28 mg nasal spray, solution. 2023; https://www.medicines.org.uk/emc/ product/10977/smpc. 15. Corkery JM, et  al. Recreational ketamine-­related deaths notified to the National Programme on Substance Abuse Deaths, England, ­1997–2019. J Psychopharmacol 2021; 35:1324–1348. 16. Green SM, et al. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Ann Emerg Med 1999; 34:492–497. 17. Cassidy S, et al. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987; 295:1021–1024. 18. Henry JA, et al. Relative mortality from overdose of antidepressants. BMJ 1995; 310:221–224. 19. Crome P. Antidepressant overdosage. Drugs 1982; 23:431–461. 20. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16:374–390. 21. Waring WS, et al. Acute myocarditis after massive phenelzine overdose. Eur J Clin Pharmacol 2007; 63:1007–1009. 22. Chand S, et al. One hundred cases of acute intoxication with minaserin hydrochloride. Pharmacopsychiatry 1981; 14:15–17. 23. Scherer D, et  al. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol 2008; 378:73–83. 24. Koseoglu Z, et al. Bradycardia and hypotension in mianserin intoxication. Hum Exp Toxicol 2010; 29:887–888. 25. Bremner JD, et al. Safety of mirtazapine in overdose. J Clin Psychiatry 1998; 59:233–235. 26. LoVecchio F, et al. Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. J Emerg Med 2008; 34:77–78. 27. Berling I, et al. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol (Phila) 2014; 52:20–24. 28. Nelson JC, et al. Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. Poison Control Centers, 2000–2014. Am J Psychiatry 2017; 174:438–450. 29. Vignali C, et al. Mirtazapine fatal poisoning. Forensic Sci Int 2017; 276:e8–e12. 30. Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology (Berl) 1992; 106 Suppl:S127–S129. 31. Myrenfors PG, et al. Moclobemide overdose. J Intern Med 1993; 233:113–115. 32. Baldwin DS, et al. Tolerability and safety of reboxetine. Rev Contemp Pharmacother 2000; 11:321–330. 33. Cheeta S, et al. Antidepressant-­related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184:41–47. 34. Barbey JT, et al. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl 15:42–48. 35. Jimmink A, et al. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 2008; 30:365–371. 36. Tarabar AF, et al. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008; 4:101–105. 37. Kraai EP, et al. Citalopram overdose: a fatal case. J Med Toxicol 2015; 11:232–236. 38. Yilmaz Z, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila) 2010; 48:207–212. 39. van Gorp F, et al. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54:404–408. 40. Gamble DE, et al. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 1986; 47:544–546. 41. Martinez MA, et  al. Investigation of a fatality due to trazodone poisoning: case report and literature review. J Anal Toxicol 2005; 29:262–268. 42. Dattilo PB, et al. Prolonged QT associated with an overdose of trazodone. J Clin Psychiatry 2007; 68:1309–1310. 43. Service JA, et al. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008; 46:71–73. 44. Caksen H, et al. Acute amitriptyline intoxication: an analysis of 44 children. Hum Exp Toxicol 2006; 25:107–110. 45. Howell C, et al. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64:192–197. 46. Hojer J, et al. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila) 2008; 46:336–337. 47. Taylor D. Venlafaxine and cardiovascular toxicity. BMJ 2010; 340:327.

Psychotropic drugs in special conditions CHAPTER 13 48. Bekka E, et al. Dose-­related hypoglycemia in venlafaxine poisoning: a retrospective cohort study. Clin Toxicol (Phila) 2022; 60:1336–1344. 49. Cooper JM, et al. Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects. Clin Toxicol (Phila) 2017; 55:18–24. 50. Russell JL, et al. Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications. Clin Toxicol (Phila) 2017; 55:352–356. 51. Allergan USA Inc. Highlights of prescribing information: VIIBRYD (vilazodone hydrochloride) tablets for oral use. 2023; https://www. allergan.com/assets/pdf/viibryd_pi. 52. Mazza MG, et al. Vortioxetine overdose in a suicidal attempt: a case report. Medicine (Baltimore) 2018; 97:e10788. 53. Isbister GK, et al. Amisulpride deliberate self-­poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust 2006; 184:354–356. 54. Ward DI. Two cases of amisulpride overdose: a cause for prolonged QT syndrome. Emerg Med Australas 2005; 17:274–276. 55. Isbister GK, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 2010; 30:391–395. 56. Lofton AL, et al. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 2005; 43:151–153. 57. Carstairs SD, et al. Overdose of aripiprazole, a new type of antipsychotic. J Emerg Med 2005; 28:311–313. 58. Forrester MB. Aripiprazole exposures reported to Texas poison control centers during 2002–2004. J Toxicol Environ Health A 2006; 69:1719–1726. 59. Taylor JE, et al. A case of intentional asenapine overdose. Prim Care Companion CNS Disord 2013; 15:PCC.13l01547. 60. Haddad PM, et al. Antipsychotic-­related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62:1649–1671. 61. Levine BS, et al. Two fatalities involving haloperidol. J Anal Toxicol 1991; 15:282–284. 62. Henderson RA, et al. Life-­threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum Exp Toxicol 1991; 10:59–62. 63. Recordati Pharmaceuticals Limited. Summary of product characteristics. Reagila (cariprazine) 1.5mg, 3mg, 4.5mg and 6mg hard capsules. 2024 (last accessed August 2024); https://www.medicines.org.uk/emc/product/9401/smpc. 64. Trenton A, et al. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17:307–324. 65. Flanagan RJ, et al. Suspected clozapine poisoning in the UK/Eire, 1992–2003. Forensic Sci Int 2005; 155:91–99. 66. Shigeev SV, et al. [Clozapine intoxication: theoretical aspects and forensic-­medical examination]. Sud Med Ekspert 2013; 56:41–46. 67. Vigneault P, et al. Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration. Pharmacol Res 2012; 66:60–65. 68. Vanda Pharmaceuticals Inc. Highlights of prescribing information: FANAPT® (iloperidone) tablets. 2021; https://www.fanapt.com/product/ pi/pdf/fanapt.pdf. 69. Amon J, et al. A case of iloperidone overdose in a 27-­year-­old man with cocaine abuse. SAGE Open Med Case Rep 2016; 4:2050313x16660485. 70. Vyas P, et al. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother 2020; 21:139–145. 71. CNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe). Summary of product characteristics. Latuda 18.5mg, 37mg and 74mg film-­coated tablets. 2022 (last accessed December 2023); https://www.medicines.org.uk/emc/product/3299/smpc. 72. Molnar GP, et al. Acute lurasidone overdose. J Clin Psychopharmacol 2014; 34:768–770. 73. Chue P, et al. A review of olanzapine-­associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003; 28:253–261. 74. Waring WS, et al. Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 2006; 25:735–740. 75. Morissette P, et al. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol 2007; 21:735–741. 76. Krka UK Ltd. Summary of product characteristics. Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 20mg tablets. 2023 (last accessed August 2024); https://www.medicines.org.uk/emc/product/14727/smpc. 77. Buckley NA, et  al. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33:199–204. 78. Li C, et al. Acute pulmonary edema induced by overdosage of phenothiazines. Chest 1992; 101:102–104. 79. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 Suppl 1:43–51. 80. Sahli ZT, et al. Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Exp Opin Drug Discov 2018; 13:103–110. 81. Vanover KE, et al. Pharmacokinetics, tolerability, and safety of ACP-­103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol 2007; 47:704–714. 82. Ngo A, et al. Acute quetiapine overdose in adults: a 5-­year retrospective case series. Ann Emerg Med 2008; 52:541–547. 83. Bertol E, et al. Overdose of quetiapine – a case report with QT prolongation. Toxics 2021; 9:339. 84. Liang CS, et al. Acute renal failure after paliperidone overdose: a case report. J Clin Psychopharmacol 2012; 32:128. 85. Lapid MI, et al. Acute dystonia associated with paliperidone overdose. Psychosomatics 2011; 52:291–294. 86. Gomez-­Criado MS, et al. Ziprasidone overdose: cases recorded in the database of Pfizer-­Spain and literature review. Pharmacotherapy 2005; 25:1660–1665. 87. Arbuck DM. 12,800-­mg ziprasidone overdose without significant ECG changes. Gen Hosp Psychiatry 2005; 27:222–223. 88. Insa Gomez FJ, et al. Ziprasidone overdose: cardiac safety. Actas Esp Psiquiatr 2005; 33:398–400. 89. Klein-­Schwartz W, et  al. Prospective observational multi-­poison center study of ziprasidone exposures. Clin Toxicol (Phila) 2007; 45:782–786. 90. Tan HH, et al. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009; 27:607–616. 91. Alipour A, et al. Torsade de pointes after ziprasidone overdose with coingestants. J Clin Psychopharmacol 2010; 30:76–77.

920 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 13 92. Spiller HA. Management of carbamazepine overdose. Pediatr Emerg Care 2001; 17:452–456. 93. Schmidt S, et al. Signs and symptoms of carbamazepine overdose. J Neurol 1995; 242:169–173. 94. Pap C, et al. Severe carbamazepine overdose associated with shock, repeated seizures and extreme high serum concentrations treated by extended intermittent hemodiafiltration. 42nd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 24–27 May 2022, Tallinn, Estonia. Clin Toxicol 2022; 60:abstract 145. 95. Alabi A, et al. Safety profile of lamotrigine in overdose. Ther Adv Psychopharmacol 2016; 6:369–381. 96. Alyahya B, et  al. Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. Clin Toxicol (Phila) 2018; 56:81–89. 97. Tuohy K, et al. Acute lithium intoxication. Dial Transplant 2003; 32:478–481. 98. Chen KP, et  al. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci 2004; 58:25–29. 99. Offerman SR, et al. Hospitalized lithium overdose cases reported to the California Poison Control System. Clin Toxicol (Phila) 2010; 48:443–448. 100. Ferrey AE, et al. Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-­poisoning. BMC Psychiatry 2018; 18:399. 101. Isbister GK, et al. Valproate overdose: a comparative cohort study of self poisonings. Br J Clin Pharmacol 2003; 55:398–404. 102. Spiller HA, et  al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 2000; 38:755–760. 103. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002; 40:789–801. 104. Eyer F, et  al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 2005; 25:376–380. 105. Robinson P, et al. Severe hypothermia in association with sodium valproate overdose. NZ Med J 2005; 118:U1681. 106. Reith DM, et al. Comparison of the fatal toxicity index of zopiclone with benzodiazepines. J Toxicol Clin Toxicol 2003; 41:975–980. 107. Isbister GK, et al. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 2004; 58:88–95. 108. Kleinman RA, et al. Benzodiazepine-­involved overdose deaths in the USA: 2000–2019. J Gen Intern Med 2022; 37:2103–2109. 109. Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004; 99:686–696. 110. Caplehorn JR, et al. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust NZ J Public Health 2002; 26:358–362. 111. Martindale Pharma an Ethypharm Group Company. Summary of product characteristics. Methadone 5mg tablets. 2023; (last accessed August 2024) https://www.medicines.org.uk/emc/product/11838/smpc. 112. Spiller HA, et al. Toxicity from modafinil ingestion. Clin Toxicol (Phila) 2009; 47:153–156. 113. Carstairs SD, et al. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol 2010; 6:307–310. 114. Russell J, et al. Retrospective assessment of toxicity following exposure to Orexin pathway modulators modafinil and suvorexant. Toxicol Commun 2019; 3:33–36. 115. Bioprojet UK Limited. Summary of product characteristics. Wakix 18 mg film-­coated tablets (pitolisant). 2023; https://www.medicines.org. uk/emc/product/14454/smpc. 116. Miljevic C, et al. A case of pregabalin intoxication. Psychiatriki 2012; 23:162–165. 117. Wood DM, et al. Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol 2010; 6:435–437. 118. Kriikku P, et al. Pregabalin and gabapentin in non-­opioid poisoning deaths. Forensic Sci Int 2021; 324:110830. 119. Trautman W, et al. Orexin antagonist overdose should not keep you up at night: mild toxicity in a large suvorexant overdose. Clinical Toxicology 2023; 61 Suppl 2: abstract 205. http://doi.org/10.1080/15563650.2023.2233835. 120. Gock SB, et al. Acute zolpidem overdose – report of two cases. J Anal Toxicol 1999; 23:559–562. 121. Garnier R, et al. Acute zolpidem poisoning – analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32:391–404. 122. De Donatis D, et al. Extremely high-­dosage zolpidem poisoning with favorable outcome. J Clin Psychopharmacol 2021; 41:222–223. 123. Pounder D, et al. Zopiclone poisoning. J Anal Toxicol 1996; 20:273–274. 124. Bramness JG, et al. Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma. J Forensic Sci 2001; 46:1247–1249.